+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Depression Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851894
  • Report
  • May 2018
  • Region: Global
  • 288 pages
  • Transparency Market Research
1 of 2

Depression Drugs Market - Overview

This report analyzes the global depression drugs market in terms of its current and future scenario. Increase in prevalence of major depression disorders, rise in government initiatives in creating awareness about depression drugs, and growth in geriatric population across the world are expected to drive the depression drugs market during the forecast period.

The report on the global depression drugs market comprises an elaborate executive summary, including a market snapshot that provides information on various segments. It also provides information and data analysis of the global market with respect to its segments based on drug class, disease type, distribution channel, and geography.  A detailed qualitative analysis of drivers and restraints, opportunities, and trends has been provided in the market overview section.  Additionally, the section comprises product pipeline analysis to help understand the scope of the market. The section also provides market share analysis in terms of segments, geography and key players, thus presenting a thorough analysis of the overall competitive scenario in the global depression drugs market. 

The global depression drugs market has been classified on the basis of drug class, disease type, distribution channel, and region. Based on drug class, the market has been categorized into atypical antipsychotics, serotonin–norepinephrine reuptake inhibitor, selective serotonin reuptake inhibitor, central nervous system (CNS) stimulant, and others. In terms of disease type, the market has been classified into major depressive disorder, schizophrenia and bipolar I disorder, selective serotonin reuptake inhibitor induced, and others. Based on distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Geographically, the global depression drugs market has been categorized into five major regions and key countries in those regions: North America (U.S.  and Canada), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, Israel, GCC, and Rest of Middle East & Africa).  

The report also profiles major players operating in the global depression drugs market based on various attributes, such as, company overview, financial overview, product portfolio, business strategies, SWOT analysis, and recent developments. Major players profiled in this report include Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Pfizer Inc., AstraZeneca, Allergan USA, Inc., Novartis AG, GlaxoSmithKline, and Takeda Pharmaceutical Company Ltd.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Segmentation
1.2. Key Research Objectives
1.3. Research Highlights

2. Assumptions and Acronyms Used

3. Research Approach & Methodology
3.1. Research Methodology overview
3.2. Project Initiation
3.3. Secondary Research Methodology
3.4. Primary Research Methodology
3.5. Analysis Research Methodology
3.6. Final Report & Conclusions Research Methodology

4. Executive Summary: Global Depression Drugs Market

5. Market Overview
5.1. Overview
5.2. Key Industry Events and Developments
5.3. Global Depression Drugs Market Forecast and Analysis
5.4. Global Depression Drugs Market Outlook

6. Market Dynamics
6.1. Drivers and Restraints Snapshot Analysis
6.2. Drivers
6.3. Restraints
6.4. Opportunities
6.5. Key Trends
6.6. Pipeline Analysis
6.7. Depression Treatment Market Value Chain Analysis

7. Global Depression Drugs Market, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Depression Drugs Market, by Drug Class
7.3.1. Atypical antipsychotics
7.3.2. Serotonin-norepinephrine reuptake inhibitors
7.3.3. Selective serotonin reuptake inhibitors
7.3.4. CNS stimulants
7.3.4. Others (Benzodiazepines and miscellaneous antidepressants)
7.4. Global Depression Drugs Market Share Analysis, by Drug Class
7.5. Global Depression Drugs Market Forecast, by Drug Class
7.6. Global Depression Drugs Market Analysis, by Drug Class

8. Global Depression Drugs Market, by Disease Type
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Global Depression Drugs Market, by Disease Type
8.3.1. Major Depressive Disorder
8.3.2. Schizophrenia and bipolar I disorder (manic depression)
8.3.3. SSRI induced
8.3.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
8.4. Global Depression Drugs Market Value Share Analysis, by Disease Type
8.5. Global Depression Drugs Market Forecast, by Disease Type
8.6. Global Depression Drugs Market Analysis, by Disease Type

9. Global Depression Drugs Market, by Distribution Channel
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Global Depression Drugs Market, by Distribution Channel
9.3.1. Hospital pharmacies
9.3.2. Retail pharmacies
9.3.3. Online pharmacies
9.4. Global Depression Drugs Market Share Analysis, by Distribution Channel
9.5. Global Depression Drugs Market Forecast, by Distribution Channel
9.6. Global Depression Drugs Market Analysis, by Distribution Channel

10. Global Depression Drugs Market, by Region
10.1. Global Depression Drugs Market Snapshot, by Country/Sub-region
10.2. Global Depression Drugs Market Analysis, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Depression Drugs Market Forecast, by Region

11. North America Depression Drugs Market Analysis
11.1. Policies and Regulations: U.S.
11.2. Key Findings
11.3. North America Depression Drugs Market Overview
11.4. North America Depression Drugs Market Value Share Analysis, by Drug Class
11.5. North America Depression Drugs Market Forecast, by Drug Class
11.5.1. Atypical antipsychotics
11.5.2. Serotonin-norepinephrine reuptake inhibitors
11.5.3. Selective serotonin reuptake inhibitors
11.5.4. CNS stimulants
11.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
11.6. North America Depression Drugs Market Value Share Analysis, by Disease Type
11.7. North America Depression Drugs Market Forecast, by Disease Type
11.7.1. Major depressive disorder
11.7.2. Schizophrenia and bipolar I disorder (manic depression)
11.7.3. Selective serotonin reuptake inhibitors induced
11.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
11.8. North America Depression Drugs Market Value Share Analysis, by Distribution Channel
11.9. North America Depression Drugs Market Forecast, by Distribution Channel
11.9.1. Hospital pharmacies
11.9.2. Retail pharmacies
11.9.3. Online pharmacies
11.10. North America Depression Drugs Market Value Share Analysis, by Country
11.11. North America Depression Drugs Market Forecast, by Country
11.11.1. U.S.
11.11.2. Canada
11.12. Market Trends North America

12. Europe Depression Drugs Market Analysis
12.1. Policies and Regulations: Europe
12.2. Key Findings
12.3. Europe Depression Drugs Market Overview
12.4. Europe Depression Drugs Market Value Share Analysis, by Drug Class
12.5. Europe Depression Drugs Market Forecast, by Drug Class
12.5.1. Atypical antipsychotics
12.5.2. Serotonin-norepinephrine reuptake inhibitors
12.5.3. Selective serotonin reuptake inhibitors
12.5.4. CNS stimulants
12.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
12.6. Europe Depression Drugs Market Value Share Analysis, by Disease Type
12.7. Europe Depression Drugs Market Forecast, by Disease Type
12.7.1. Major depressive disorder
12.7.2. Schizophrenia and bipolar I disorder (manic depression)
12.7.3. Selective serotonin reuptake inhibitors induced
12.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
12.8. Europe Depression Drugs Market Value Share Analysis, by Distribution Channel
12.9. Europe Depression Drugs Market Forecast, by Distribution Channel
12.9.1. Hospital pharmacies
12.9.2. Retail pharmacies
12.9.3. Online pharmacies
12.10. Europe Depression Drugs Market Value Share Analysis, by Country
12.11. Europe Depression Drugs Market Forecast, by Country
12.11.1. Germany
12.11.2. France
12.11.3. Italy
12.11.4. Spain
12.11.5. U.K.
12.11.6. Rest of Europe
12.12. Market Trends Europe

13. Asia Pacific Depression Drugs Market Analysis
13.1. Policies and Regulations: Asia Pacific
13.2. Key Findings
13.3. Asia Pacific Depression Drugs Market Overview
13.4. Asia Pacific Depression Drugs Market Value Share Analysis, by Drug Class
13.5. Asia Pacific Depression Drugs Market Forecast, by Drug Class
13.5.1. Atypical antipsychotics
13.5.2. Serotonin-norepinephrine reuptake inhibitors
13.5.3. Selective serotonin reuptake inhibitors
13.5.4. CNS stimulants
13.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
13.6. Asia Pacific depression drugs Market Value Share Analysis, by Disease Type
13.7. Asia Pacific Depression Drugs Market Forecast, by Disease Type
13.7.1. Major depressive disorder
13.7.2. Schizophrenia and bipolar I disorder (manic depression)
13.7.3. Selective serotonin reuptake inhibitors induced
13.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
13.8. Asia Pacific Depression Drugs Market Value Share Analysis, by Distribution Channel
13.9. Asia Pacific Depression Drugs Market Forecast, by Distribution Channel
13.9.1. Hospital pharmacies
13.9.2. Retail pharmacies
13.9.3. Online pharmacies
13.10. Asia Pacific Depression Drugs Market Value Share Analysis, by Country
13.11. Asia Pacific Depression Drugs Market Forecast, by Country
13.11.1. China
13.11.2. Japan
13.11.3. India
13.11.4. Australia & New Zealand
13.11.5. Rest of Asia Pacific
13.12. Market Trends Asia Pacific

14. Latin America Depression Drugs Market Analysis
14.1. Policies and Regulations: Latin America
14.2. Key Findings
14.3. Latin America Depression Drugs Market Overview
14.4. Latin America Depression Drugs Market Value Share Analysis, by Drug Class
14.5. Latin America Depression Drugs Market Forecast, by Drug Class
14.5.1. Atypical antipsychotics
14.5.2. Serotonin-norepinephrine reuptake inhibitors
14.5.3. Selective serotonin reuptake inhibitors
14.5.4. CNS stimulants
14.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
14.6. Latin America depression drugs Market Value Share Analysis, by Disease Type
14.7. Latin America Depression Drugs Market Forecast, by Disease Type
14.7.1. Major depressive disorder
14.7.2. Schizophrenia and bipolar I disorder (manic depression)
14.7.3. Selective serotonin reuptake inhibitors induced
14.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
14.8. Latin America Depression Drugs Market Value Share Analysis, by Distribution Channel
14.9. Latin America Depression Drugs Market Forecast, by Distribution Channel
14.9.1. Hospital pharmacies
14.9.2. Retail pharmacies
14.9.3. Online pharmacies
14.10. Latin America Depression Drugs Market Value Share Analysis, by Country
14.11. Latin America Depression Drugs Market Forecast, by Country
14.11.1. Brazil
14.11.2. Mexico
14.11.3. Rest of Latin America
14.12. Market Trends Latin America

15. Middle East & Africa Depression Drugs Market Analysis
15.1. Policies and Regulations: Middle East & Africa
15.2. Key Findings
15.3. Middle East & Africa Depression Drugs Market Overview
15.4. Middle East & Africa Depression Drugs Market Value Share Analysis, by Drug Class
15.5. Middle East & Africa Depression Drugs Market Forecast, by Drug class
15.5.1. Atypical antipsychotics
15.5.2. Serotonin-norepinephrine reuptake inhibitors
15.5.3. Selective serotonin reuptake inhibitors
15.5.4. CNS stimulants
15.5.5. Others (Benzodiazepines and miscellaneous antidepressants)
15.6. Middle East & Africa Depression Drugs Market Value Share Analysis, by Disease Type
15.7. Middle East & Africa Depression Drugs Market Forecast, by Disease Type
15.7.1. Major depressive disorder
15.7.2. Schizophrenia and bipolar I disorder (manic depression)
15.7.3. Selective serotonin reuptake inhibitors induced
15.7.4. Others (attention deficit hyperactivity disorder and anxiety disorders)
15.8. Middle East & Africa Depression Drugs Market Value Share Analysis, by Distribution Channel
15.9. Middle East & Africa Depression Drugs Market Forecast, by Distribution Channel
15.9.1. Hospital pharmacies
15.9.2. Retail pharmacies
15.9.3. Online pharmacies
15.10. Middle East & Africa Depression Drugs Market Value Share Analysis, by Country
15.11. Middle East & Africa Depression Drugs Market Forecast, by Country
15.11.1. GCC
15.11.2. South Africa
15.11.3. Israel
15.11.4. Rest of Middle East & Africa
15.12. Market Trends Middle East & Africa

16. Competition Landscape
16.1. Competition Matrix
16.2. Depression Drugs Market Share Analysis, by Company
16.3. Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
16.3.1. Otsuka Pharmaceutical Co., Ltd.
16.3.1.1. Company Description
16.3.1.2. Financial Overview
16.3.1.3. Recent Developments
16.3.1.4. Strategic Overview
16.3.1.4. SWOT Analysis
16.3.2. Eli Lilly and Company
16.3.2.1. Company Description
16.3.2.2. Financial Overview
16.3.2.3. Strategic Overview
16.3.2.4. SWOT Analysis
16.3.3. Pfizer, Inc.
16.3.3.1. Company Description
16.3.3.2. Financial Overview
16.3.3.3. Strategic Overview
16.3.3.4. SWOT Analysis
16.3.4. AstraZeneca plc.
16.3.4.1. Company Description
16.3.4.2. Financial Overview
16.3.4.3. SWOT Analysis
16.3.5. Novartis AG
16.3.5.1. Company Description
16.3.5.2. Financial Overview
16.3.5.3. Strategic Overview
16.3.5.4. SWOT Analysis
16.3.6. GlaxoSmithKline plc
16.3.6.1. Company Description
16.3.6.2. Financial Overview
16.3.6.3. Strategic Overview
16.3.6.4. Recent Developments
16.3.6.5. SWOT Analysis
16.3.7. Takeda Pharmaceutical Company Ltd
16.3.7.1. Company Description
16.3.7.2. Financial Overview
16.3.7.3. Strategic Overview
16.3.7.4. SWOT Analysis
16.3.8. Sebela Pharmaceutical Inc.
16.3.8.1. Company Description
16.3.8.2. Financial Overview
16.3.8.3. Strategic Overview
16.3.8.3. SWOT Analysis
16.3.9. Allergan USA, Inc.
16.3.9.1. Company Description
16.3.9.2. Financial Overview
16.3.9.3. Strategic Overview
16.3.9.3. SWOT Analysis
16.3.10. Johnson & Johnson
16.3.10.1. Company Description
16.3.10.2. Financial Overview
16.3.10.3. Strategic Overview
16.3.10.4. SWOT Analysis
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll